* having symptoms suggestive of covid-19 infection * hiv infection * active hepatitis b infection. * renal failure with estimated glomerular filtration rate (gfr) \< 60 ml/min) and patients on hemodialysis. * osteoporosis * myasthenia gravis * pre-existent maculopathy. * retinitis pigmentosa * bradycardia \< 50bpm * weight \< 40kg * participant with any immunosuppressive condition or hematological disease. * have taken any medications such as prep against sars-cov-2 from march 1, 2020 until trial entry (also includes prep for hiv). * treatment with drugs that may prolong qt in the last month before randomization for more than 7 days including: azithromycin, chlorpromazine, cisapride, clarithromycin, domperidone, droperidol, erythromycin, halofantrine, haloperidol, lumefantrine, mefloquine, methadone, pentamidine, procainamide, quinidine, quinine, sotalol, sparfloxacin, thioridazine, amiodarone. * breastfeeding * known allergy to any of the medication used in this trial

* having symptoms suggestive of covid-19 infection * hiv infection * active hepatitis b infection. * renal failure with estimated glomerular filtration rate (gfr) \< 60 ml/min) and patients on hemodialysis. * osteoporosis * myasthenia gravis * pre-existent maculopathy. * retinitis pigmentosa * bradycardia \< 50bpm * weight \< 40kg * participant with any immunosuppressive condition or hematological disease. * have taken any medications such as prep against sars-cov-2 from march 1, 2020 until trial entry (also includes prep for hiv). * treatment with drugs that may prolong qt in the last month before randomization for more than 7 days including: azithromycin, chlorpromazine, cisapride, clarithromycin, domperidone, droperidol, erythromycin, halofantrine, haloperidol, lumefantrine, mefloquine, methadone, pentamidine, procainamide, quinidine, quinine, sotalol, sparfloxacin, thioridazine, amiodarone. * breastfeeding * known allergy to any of the medication used in this trial

- having symptoms suggestive of covid-19 infection - hiv infection - active hepatitis b infection. - renal failure with estimated glomerular filtration rate (gfr) < 60 ml/min) and patients on hemodialysis. - osteoporosis - myasthenia gravis - pre-existent maculopathy. - retinitis pigmentosa - bradycardia < 50bpm - weight < 40kg - participant with any immunosuppressive condition or hematological disease. - have taken any medications such as prep against sars-cov-2 from march 1, 2020 until trial entry (also includes prep for hiv). - treatment with drugs that may prolong qt in the last month before randomization for more than 7 days including: azithromycin, chlorpromazine, cisapride, clarithromycin, domperidone, droperidol, erythromycin, halofantrine, haloperidol, lumefantrine, mefloquine, methadone, pentamidine, procainamide, quinidine, quinine, sotalol, sparfloxacin, thioridazine, amiodarone. - breastfeeding - known allergy to any of the medication used in this trial

- having symptoms suggestive of covid-19 infection - hiv infection - active hepatitis b infection. - renal failure with estimated glomerular filtration rate (gfr) < 60 ml/min) and patients on hemodialysis. - osteoporosis - myasthenia gravis - pre-existent maculopathy. - retinitis pigmentosa - bradycardia < 50bpm - weight < 40kg - participant with any immunosuppressive condition or hematological disease. - have taken any medications such as prep against sars-cov-2 from march 1, 2020 until trial entry (also includes prep for hiv). - treatment with drugs that may prolong qt in the last month before randomization for more than 7 days including: azithromycin, chlorpromazine, cisapride, clarithromycin, domperidone, droperidol, erythromycin, halofantrine, haloperidol, lumefantrine, mefloquine, methadone, pentamidine, procainamide, quinidine, quinine, sotalol, sparfloxacin, thioridazine, amiodarone. - breastfeeding - known allergy to any of the medication used in this trial